louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01346566: Prospective Study of Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses
Official title: Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses: A Prospective Case Series
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Lens Subluxation
Keywords: Cionni Ring
In-the-bag IOL
Subluxated lenses
Intraoperative Performance
Postoperative Outcome
Lead sponsor: Iladevi Cataract and IOL Research Center
Sponsor class: OTHER
First posted: 2011-05-03
Enrollment: 33
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to report the intraoperative performance and postoperative outcomes of the Cionni-modified capsule tension ring implantation in eyes with subluxated lenses.

Detailed description: The introduction of endocapsular stabilising devices have significantly improved the management of zonular weakness, allowing for in-the-bag IOL implantation. The Cionni modified capsule tension ring (M-CTR) has an anterior eyelet that provides for fixation of the capsular bag without violating its integrity. Adult and pediatric studies have shown the usefulness of the M-CTR to manage zonular weakness. However, there are very few prospective studies that show the outcomes following implantation of the M-CTR and in-the-bag IOL on a longterm basis. Therefore, the investigators decided to carry out this study to report the intraoperative performance and postoperative outcomes on a longterm basis following M-CTR and in-the-bag intraocular lens (IOL) implantation.

Eligibility criteria: Inclusion Criteria:

* Subluxated Lenses
* Traumatic or Non-traumatic etiology

Exclusion Criteria:

* Dislocated Lenses

Primary outcomes:
measure: IOL Centration
timeFrame: 4 years follow-up
Secondary outcomes:
measure: Complications
timeFrame: 4 years follow-up
measure: IOP
timeFrame: 4 years
measure: Posterior Capsule Opacification
timeFrame: 4 years
Other outcomes:
Locations:
city: Ahmedabad
country: India
facility: Iladevi Cataract & IOL Research Centre
state: Gujarat
Study officials:
affiliation: Iladevi Cataract & IOL Research Centre
name: Abhay R Vasavada, MS, FRCS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vasavada AR, Praveen MR, Vasavada VA, Yeh RY, Srivastava S, Koul A, Trivedi RH. Cionni ring and in-the-bag intraocular lens implantation for subluxated lenses: a prospective case series. Am J Ophthalmol. 2012 Jun;153(6):1144-53.e1. doi: 10.1016/j.ajo.2011.11.012. Epub 2012 Feb 7.
Clinical trial NCT04270266: Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
Official title: Mind-Body Medicine for Adolescents and Young Adults (AYA) Coping With Lymphoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Lymphoma
Keywords: All types of lymphoma
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2020-02-17
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This trial studies how well a mind-body intervention works in improving overall quality of life in adolescents and young adults with lymphoma. A meditation based mind-body intervention may help lower distress, depressive symptoms, and anxiety in adolescents and young adults coping with lymphoma.

Detailed description: PRIMARY OBJECTIVE:

I. Examine the feasibility of the mind-body intervention in adolescents and young adults (AYAs) with lymphoma.

SECONDARY OBJECTIVE:

I. Establish the initial intervention efficacy regarding psychological distress and cancer symptoms (tertiary objective) relative to an attention control (AC) group.

EXPLORATORY OBJECTIVE:

I. Explore mediation (e.g., mindfulness, compassion, social connection, inflammatory processes) and moderation (e.g., demographic and medical factors) of the intervention effects.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients attend meditation group sessions over 75 minutes once weekly for up to 5 weeks.

GROUP II: Patients attend educational group sessions over 75 minutes once weekly for up to 5 weeks.

After completion of study intervention, patients are followed at 6 and 12 weeks.

Eligibility criteria: Inclusion Criteria:

* Participants between the ages of 18-39 diagnosed within 6 months with stage I-IV Lymphoma (all types)
* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or below
* Having access to the internet
* Able to read, write and speak English

Exclusion Criteria:

* Major psychiatric or cognitive deficits that would impede the completion of self-report instruments as deemed by the clinical team
* Regular (self-defined) participation in psychotherapy or a formal cancer support group

Primary outcomes:
measure: Mind-body intervention in (AYAs) Adolescents and Young Adults with Lymphoma Questionnaire
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Psychological distress and cancer symptoms (tertiary objective) relative to an attention control (AC) group Questionnaire
timeFrame: Up to 12 weeks
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Kathrin Milbury
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02714166: Evaluation of the Irritation Potential of Products in Human Eyes
Official title: Evaluation of the Irritation Potential of Products in Human Eyes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-03-21
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To evaluate the human eye irritation potential of one test sunscreen formulation.


Eligibility criteria: Inclusion Criteria:

* Must be healthy males or females between the ages of 18 to 60 years inclusive with no medical conditions of the eyes.
* Do not wear contact lenses or, if he/she does wear contact lenses, is willing to refrain from wearing these during the test period.
* Willing to report any medications taken during the study.
* Willing to have the test materials instilled into the eyes and follow all protocol requirements.
* Have been informed and have given written consent to participate in the study.

Exclusion Criteria:

* Has ocular disease or peri-orbital dermatitis or trauma, infections or chronic eye conditions that may affect the study outcome.
* Has systemic illness which affects the eyes, including diabetes, thyroid disease, sarcoidosis, hypertension, atherosclerosis, lupus, multiple sclerosis, sickle cell disease, AIDs (Acquired Immune Deficiency Syndrome), severer rheumatoid arthritis. results as determined by the investigator.
* Must not have a history of pre-existing sensitivity or other types of allergy to any eye products.
* Must not have received and used an Investigational New Drug within the thirty days immediately preceding the study.

Primary outcomes:
measure: Subjective assessment of discomfort in the eyes assessed by 5 point scale.
timeFrame: Up to 1 day
measure: Intensity of Lacrimation assessed by 5 grading scale.
timeFrame: Up to 1 day
measure: Intensity of Bulbar Conjunctiva Irritation assessed by 4 grading scale.
timeFrame: Up to 1 day
measure: Intensity of Palpebral Conjunctiva Irritation assessed by 4 grading scale.
timeFrame: Up to 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: St. Petersburg
country: United States
state: Florida
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT06815666: BAL Fluid Biomarkers in Sarcoma
Official title: Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Soft Tissue Sarcoma (STS)
Bronchoalveolar Lavage (BAL)
Bronchoalveolar Lavage Fluid
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2025-02-07
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years
2. Ability to understand and willingness to sign a written informed consent document
3. Diagnosed with soft tissue sarcoma
4. Undergoing resection of lung lesion as part of standard care

Exclusion Criteria:

1. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years

Primary outcomes:
measure: Identification of NET-related inflammatory biomarkers using BALF and TA diagnostic tools
timeFrame: 2 years
measure: Quantification of NET-related inflammatory biomarkers using BALF and TA diagnostic tool
timeFrame: 2 years
measure: Correlation of NET-related inflammatory markers using BALF and TA diagnostic tool with the extent of metastatic dissemination
timeFrame: 2 years
Secondary outcomes:
measure: Analysis of NET-related inflammatory biomarkers using BALF and TA diagnostic tool
timeFrame: 2 years
measure: Correlation between NET-related inflammatory biomarkers using BALF and TA diagnostic tool
timeFrame: 2 years
measure: NET-related inflammatory biomarker differences for BALF and TA diagnostic tools
timeFrame: 2 years
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network
state: Ontario
Study officials:
References:
Clinical trial NCT06879366: Evaluation of the Efficacy of Aloe-Vera el Versus Bezydamine Hydrochloride in the Prevention of Radiation Induced Oral Mucositis A Randamized Controlled Clinical Trial
Official title: Evaluation of the Efficacy of Aloe-Vera el Versus Bezydamine Hydrochloride in the Treatment of Radiation Induced Oral Mucositis A Randamized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Head and Neck Cancer Patients Treated With Radiotherapy
Lead sponsor: October 6 University
Sponsor class: OTHER
First posted: 2025-03-17
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Background and Rationale Oral mucositis (OM) is one of the most debilitating toxic side effects of radiotherapy and chemotherapy. \]Radiation-induced OM occurs due to the generation of free radicals, which induce mitochondrial dysfunction resulting in increased oxidative stress, DNA damage and cell apoptosis. Epidermal growth factor (EGF) levels were decreased in patients with severe OM, and patients with lower levels of EGF prior to therapy may indicate increased risk of mucosal damage during RT

Objectives:

The purpose of this study is for Evaluation of the efficacy of aloe-vera gel versus standard treatment as a new option in the treatment of radiation-induced oral mucositis

Study population \& Sample size :

40 patient proven to have Head and neck cancer , requiring radiotherapy.

Study Design:

RCT. The patients are randomized and divided into 2 groups , group A will use alovera gel , Group B will use benzylamide gel, EGF will be measured in saliva before and after 4 weeks treatment Methods Patient's visits will be at baseline, 2 weeks and 4 weeks. At follow up visits patients will be instructed to bring back the consumed container to check that they had totally consumed their previous supply before giving them the new one. Saliva collection to measure EGF by ELIZA


Eligibility criteria: Inclusion Criteria:

* The study will include patients who are diagnosed with radiation-induced oral mucositis with any of its grades as scored by the world health organization (WHO) oral mucositis grading scale.

Exclusion Criteria:

* patients under the age of 18 ,patients receiving any previous treatment for oral mucositis during the last 2 weeks, allergy to aloe-vera, patients with chronic liver disease, infectious diseases (HIV, HBV,HCV,....), immune system dysfunction, haematological diseases and pregnancy or breast-feeding

Primary outcomes:
measure: 1) Mucositis score
timeFrame: 0, 2 weeks , weeks, 6 weeks and 10 weeks
measure: pain score
timeFrame: 0, 2,4,6, and 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT01477866: Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer
Official title: Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Colonic Neoplasms
Lead sponsor: University of Palermo
Sponsor class: OTHER
First posted: 2011-11-23
Enrollment: 250
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main aim of the present study is to test the efficacy and safety of CITOGENEX administration in patients with colon-rectal cancer.

Detailed description: CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type). These subspecies of probiotics bacteria have been shown to be effective in improving the immunity. Several trials are currently underway, in order to evaluate the effects of probiotics as potential novel therapies in addition to traditional therapeutic approaches. Although probiotics do not play an anti-tumor action per se, these agents may significantly contribute to decrease the typical side effects due to traditional anti-tumor treatments, such as gastrointestinal symptoms, immunity deficit, as well as the alterations in the gut lymphoid tissue.

It is therefore expected that CITOGENEX may have several significant beneficial effects in patients under anti-tumor treatments. In order to test this hypothesis, we will perform a randomized, single-blind, two-arms, prospective study in patients with colon-rectal cancer.

Eligibility criteria: Inclusion Criteria:

* stage IIIa-IIIc (AJCC/TNM)

Primary outcomes:
measure: All cause mortality
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Palermo
country: Italy
facility: University of Palermo
state: PA
Study officials:
affiliation: University of Palermo
name: Giovanni Tomasello, MD
role: STUDY_DIRECTOR
affiliation: University of Palermo
name: Francesco Cappello, MD
role: STUDY_CHAIR
affiliation: University of Palermo
name: Provvidenza Damiani, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Palermo
name: Manfredi Rizzo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01512966: Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)
Official title: An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Macular Edema
Keywords: Diabetic Macular Edema
DME
VEGF Trap-Eye
best-corrected visual acuity (BCVA)
Lead sponsor: Bayer
Sponsor class: INDUSTRY
Collaborators: name: Regeneron Pharmaceuticals
First posted: 2012-01-20
Enrollment: 73
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will assess the safety and tolerability of intravitreally (IVT) administered VEGF Trap-Eye in Japanese subjects with diabetic macular edema (DME) over the period of one year.


Eligibility criteria: Inclusion Criteria:

* Adults ≥ 18 years with type 1 or 2 diabetes mellitus
* Subjects with DME (diabetic macular edema) secondary to diabetes mellitus involving the center of the macula in the study eye
* BCVA (best-corrected visual acuity) ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 24 (20/40 to 20/320) in the study eye

Exclusion Criteria:

* Active proliferative diabetic retinopathy (PDR) in the study eye
* Uncontrolled diabetes mellitus, as defined by HbA1c \>12%
* Only 1 functional eye even if that eye is otherwise eligible for the study

Primary outcomes:
measure: Adverse Event collection
timeFrame: Week 52
Secondary outcomes:
measure: Change from baseline in BCVA (best corrected visual acuity) letter score
timeFrame: Week 52
Other outcomes:
Locations:
city: Matsuyama
country: Japan
state: Ehime
city: Maebashi
country: Japan
state: Gunma
city: Kobe
country: Japan
state: Hyogo
city: Mito
country: Japan
state: Ibaraki
city: Kita
country: Japan
state: Kagawa
city: Kawasaki
country: Japan
state: Kanagawa
city: Sendai
country: Japan
state: Miyagi
city: Kashihara
country: Japan
state: Nara
city: Suita
country: Japan
state: Osaka
city: Otsu
country: Japan
state: Shiga
city: Shimotsuke
country: Japan
state: Tochigi
city: Kagoshima
country: Japan
city: Kyoto
country: Japan
city: Okayama
country: Japan
city: Osaka
country: Japan
city: Osaka
country: Japan
city: Saga
country: Japan
city: Wakayama
country: Japan
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01216566: Computerized Mobilization of the Cervical Spine Utilizing the Occiflex Device for the Treatment of Chronic Neck Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Neck Pain
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
Collaborators: name: Headway Ltd.
First posted: 2010-10-07
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the efficacy and safety of the Occiflex device in the treatment of neck pain.


Eligibility criteria: Inclusion Criteria:

* Patients with chronic neck pain: post-whiplash injury, myofacial pain, cervical facet joint disease and idiopathic chronic neck pain

Exclusion Criteria:

* Radiculopathy
* Myelopathy
* Cerebral vascular disease
* Malignancy
* Osteoporosis
* Cervical disc herniation

Primary outcomes:
measure: Safety of computerized continuous mobilization of the cervical spine
timeFrame: one year
Secondary outcomes:
measure: Efficacy of computerized mobilization of treatment of patients with chronic neck pain
timeFrame: one year
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT05585866: Propofol and Sevoflurane Anesthesia in Colorectal Cancer Surgery: Incidence of Acute Kidney Injury
Official title: Propofol and Sevoflurane Anesthesia in Colorectal Cancer Surgery: Incidence of Acute Kidney Injury
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Acute Kidney Injury
Cancer Colorectal
Keywords: sevoflurane
propofol
plasma creatinine
Lead sponsor: Uppsala University
Sponsor class: OTHER
First posted: 2022-10-19
Enrollment: 4000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who underwent colorectal cancer resection surgery and gave consent to participate in the CAN trial.

Brief summary: The goal of this observational study is to compare anesthetic modalities (intravenous propofol anesthesia with sevoflurane gas anesthesia) in patients who underwent colorectal cancer resection surgery regarding the outcome of acute kidney injury.

The main questions it aims to answer are:

* is there a difference in acute kidney injury incidence in the two anesthetic modalities?
* is there a difference in plasma creatinine between the two anesthetic modalities?
* are there any patient characteristics or intraoperative factors that effect the incidence of acute kidney injury in either anesthetic modality?

The study will analyze data from the CAN clinical trial database. (Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia, NCT01975064)


Eligibility criteria: Inclusion Criteria:

* colorectal surgery and participant in the CAN trial

Exclusion Criteria:

* missing blood samples

Primary outcomes:
measure: Acute Kidney Injury
timeFrame: Within 10 days of surgery
measure: Changes in plasma creatinine
timeFrame: Within 30 days of surgery
Secondary outcomes:
measure: AKI incidence in the cardiovascular disease population
timeFrame: Within 10 days of surgery
measure: Association of sex on AKI incidence
timeFrame: Within 10 days of surgery
measure: Association of age on AKI incidence
timeFrame: Within 10 days of surgery
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Uppsala University
Study officials:
References:
Clinical trial NCT02933866: Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
Official title: A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS Topical Product in Patients With Mild to Severe Scalp Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Scalp Psoriasis
Lead sponsor: Taro Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2016-10-14
Enrollment: 371
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis

Detailed description: To evaluate the therapeutic efficacy and safety of DSXS topical product (Taro Pharmaceuticals, U.S.A., Inc.) compared to a Vehicle topical product (Taro Pharmaceuticals, U.S.A., Inc.) in patients with mild to severe scalp psoriasis.

Eligibility criteria: Inclusion Criteria:

* Male or non-pregnant, non-lactating females 18 years of age and older.

Exclusion Criteria:

* Females who are pregnant, lactating or likely to become pregnant during the study.

Primary outcomes:
measure: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success
timeFrame: Day 29
Secondary outcomes:
Other outcomes:
Locations:
city: Hawthorne
country: United States
facility: Taro Pharmaceuticals USA, Inc.
state: New York
Study officials:
affiliation: http://www.novumprs.com/contact
name: Novum Pharmaceutical Research Services
role: STUDY_CHAIR
References: